A number of additional patients are in screening and the company will allow those patients to complete the process and be either randomized into the trial or disqualified, in accordance with the trial protocol.
The company expects to report top line results of the trial in the second quarter of 2006. And it expects to report top line results of ARIES-2, the other pivotal phase III trial of ambrisentan in pulmonary arterial hypertension (PAH), in December of this year.
“Based on the properties of the compound and the results of our phase II trial, we believe ambrisentan’s efficacy and safety profile may position it as the best-in-class among endothelin receptor antagonists,” said William Freytag, president and CEO of Myogen.